Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2008-06-16 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Trading Halt 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt for Sun Biomedical Limited securities pending a forthcoming announcement. It does not contain financial data, report content, or detailed information about company performance or governance. The document is short (651 characters) and serves as a regulatory announcement about trading status rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2008-06-16 English
Trading Halt Request 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to the ASX Limited requesting a trading halt pursuant to ASX Listing Rule 17.1. It explicitly states that the halt is pending the release of an announcement related to a proposed capital raising. The content is short (1200 characters) and focuses solely on the request for a trading halt, not on the details of the capital raising itself. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising activities. It is not an announcement of a report publication or a regulatory filing, but a direct update on capital raising activity.
2008-06-16 English
Appendix 3B 8 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new ordinary shares, options, their terms, issue price, purpose, and application for quotation on the ASX (Australian Securities Exchange). The document includes sections on securities issued, quotation agreements, and compliance warranties related to the listing of new securities. This type of document is a formal announcement related to capital changes, specifically new share issues and securities quotation. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital issuance and listing. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (10,197 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2008-06-05 English
Market Update 22 pages ?Kb
Regulatory Filings
2008-06-03 English
Avitar litigation and ShockRounds 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX Company Announcement dated 22 May 2008. It provides clarifications regarding previous announcements about litigation settlement and technology acquisition discussions. The content is brief (2093 characters), focuses on updates about legal and business matters, and does not contain financial statements or detailed financial data. It is not a full report, earnings release, or management discussion. It is also not a certification or voting result. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement providing updates on company matters that do not fit other specific categories.
2008-05-19 English
Chairman`s Address to Shareholders 3 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Chairman’s Address at General Meeting' and contains a detailed update on the company's financial performance, capital raising plans, business initiatives, legal and regulatory matters, and future outlook. It is a speech or presentation given at a general meeting, providing shareholders with information about the company's status and plans. The content is not a formal financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or regulatory filing. It fits the description of materials shared during a general meeting, specifically the Annual General Meeting (AGM). Therefore, the document is best classified as AGM Information (AGM-R). The document length (5036 characters) supports it being a substantive presentation rather than a short announcement.
2008-05-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.